Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
22/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
21/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
09/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
06/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
06/03/15	Wall Street closes up slightly ahead of jobs report	RE
05/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

08/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
08/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
08/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

06/03/15	Wall Street se reprend un peu dans un climat d'attente
06/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	01/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	+3.42%	+49.37%	+94.17%	74.31B
ARGENX SE	+2.76%	-1.60%	+22.80%	+78.53%	56.95B
LONZA GROUP AG	+0.28%	-1.30%	+3.45%	+34.36%	48.3B
REVOLUTION MEDICINES, INC.	-3.35%	-2.48%	+328.08%	+696.33%	44.51B
IQVIA HOLDINGS INC.	-0.47%	-2.01%	+28.56%	+32.69%	43.8B
BEONE MEDICINES AG	+1.91%	+0.64%	+6.70%	+111.42%	41.12B
CELLTRION, INC.	-0.11%	+2.30%	+9.19%	+58.68%	31.07B
WUXI BIOLOGICS (CAYMAN) INC.	+4.51%	+8.43%	+37.27%	+34.97%	28.97B
BIONTECH SE	+0.41%	-0.89%	-7.10%	-12.16%	24.53B
Average	+1.07%	-0.20%	+53.15%	+125.44%	43.73B
Weighted average by Cap.	+1.30%	-0.50%	+57.06%	+133.85%